Giovanni G.
- Country
- Italy
- Department
- Malattie Infettive
Research Overview
- Efficacy and Safety of Anakinra in Patients with Post-Acute COVID-19 Syndrome: A Double-Blind, Randomized, Placebo-Controlled Trial
- Comparative Study of Integrase Inhibitor Regimen Versus Boosted Protease Inhibitor Regimen in Late-Presenting Advanced HIV-1 Patients
- Evaluation of Semaglutide for Weight Reduction in Patients with HIV and Obesity: A Randomized, Controlled, Open-Label Trial
Data & Insights
Has run more than one trial at 6 of 50 partner sites.
Specializations
HIV Research
The investigator specializes in therapeutic approaches for advanced HIV infection, with particular focus on comparative treatment strategies involving Integrase Inhibitor and Protease Inhibitor regimens.
- Late-stage HIV management
- Antiretroviral therapy optimization
- Treatment protocols for late presenters
Research interests encompass the optimization of treatment strategies for patients who present late in their HIV-1 infection course.
Post-COVID Care
The investigator conducts research in Post-acute COVID-19 syndrome (PACS), exploring innovative therapeutic approaches including lifestyle interventions combined with geroscience-based treatments.
- Physical performance improvement
- Aging trajectory modification
- Immune function restoration
Therapeutic focus includes the evaluation of metformin and rapamycin in combination with diet and exercise interventions.
Immunological Interventions
The investigator explores innovative immunological treatments for persistent respiratory symptoms, specifically investigating anakinra therapy in PACS patients.
- Respiratory symptom management
- Immune system modulation
- Clinical progression monitoring
Research encompasses the evaluation of immunological interventions for post-COVID complications.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.